Feature Article | Seattle-area biotech led by ex-Athira CEO Leen Kawas raises $35M for hepatitis D drug

EIT Pharma has closed an oversubscribed $35 million Series A led by Propel Bio Partners. This piece covers what the round funds — FDA review, manufacturing, and commercial prep for lonafarnib, the Kirkland company's oral candidate for chronic hepatitis D — and how the asset came to EIT through the 2024 bankruptcy sale of Eiger BioPharmaceuticals.

Read the Full Article Here